241 related articles for article (PubMed ID: 23359154)
21. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.
Rouanet M; Lebrin M; Gross F; Bournet B; Cordelier P; Buscail L
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594388
[TBL] [Abstract][Full Text] [Related]
22. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
[TBL] [Abstract][Full Text] [Related]
23. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
24. Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine.
Meng Y; Efimova EV; Hamzeh KW; Darga TE; Mauceri HJ; Fu YX; Kron SJ; Weichselbaum RR
Mol Ther; 2012 May; 20(5):1046-55. PubMed ID: 22334019
[TBL] [Abstract][Full Text] [Related]
25. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
27. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment.
Osborne N; Sundseth R; Burks J; Cao H; Liu X; Kroemer AH; Sutton L; Cato A; Smith JP
Cancer Immunol Immunother; 2019 Oct; 68(10):1635-1648. PubMed ID: 31549214
[TBL] [Abstract][Full Text] [Related]
28. [Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma].
Tan G; Wang ZY; Wang XG; Cheng L; Yin S
Ai Zheng; 2006 Sep; 25(9):1082-6. PubMed ID: 16965646
[TBL] [Abstract][Full Text] [Related]
29. Novel pancreatic cancer vaccines could unleash the army within.
Springett GM
Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
[TBL] [Abstract][Full Text] [Related]
30. [Probability of vaccine therapy for pancreas cancer].
Takahashi M; Togou S; Yamaoka H; Ichikawa H; Shimada H; Cheever MA
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1676-8. PubMed ID: 8886043
[TBL] [Abstract][Full Text] [Related]
31. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
Jaffee EM; Hruban RH; Biedrzycki B; Laheru D; Schepers K; Sauter PR; Goemann M; Coleman J; Grochow L; Donehower RC; Lillemoe KD; O'Reilly S; Abrams RA; Pardoll DM; Cameron JL; Yeo CJ
J Clin Oncol; 2001 Jan; 19(1):145-56. PubMed ID: 11134207
[TBL] [Abstract][Full Text] [Related]
32. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
33. Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Taniyama K; Kamiike W; Mori M; Doki Y
Cancer Sci; 2013 Mar; 104(3):282-90. PubMed ID: 23240661
[TBL] [Abstract][Full Text] [Related]
34. Vaccines for pancreatic cancer.
Soares KC; Zheng L; Edil B; Jaffee EM
Cancer J; 2012; 18(6):642-52. PubMed ID: 23187853
[TBL] [Abstract][Full Text] [Related]
35. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives.
Yee NS
Curr Mol Pharmacol; 2016; 9(3):231-241. PubMed ID: 26177643
[TBL] [Abstract][Full Text] [Related]
37. Immunoprevention of Pancreatic Cancer.
Rao CV; Mohammed A; Asch AS; Janakiram NB
Curr Med Chem; 2018; 25(22):2576-2584. PubMed ID: 28240168
[TBL] [Abstract][Full Text] [Related]
38. Cancer immunotherapy using cells modified with cytokine genes.
Kowalczyk DW; Wysocki PJ; Mackiewicz A
Acta Biochim Pol; 2003; 50(3):613-24. PubMed ID: 14515144
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.
Xuan W; Yan Y; Wan M; Wu X; Ji D; Wang L; Lin C; Chen Y; Yu Y; Zhang X
Int Immunopharmacol; 2015 Jul; 27(1):95-103. PubMed ID: 25907246
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
